Label (53401 0007 30)
Pregabalin Capsule
Product Images NDC 53401-007
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 53401-007). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Aphena (Aphena)
Figure 1 (Pregabalin Fig01)
Figure 2 (Pregabalin Fig02)
This text appears to show data related to patient improvement after taking Pregabalin 160 mg for 3 days. The table shows the percent improvement in pain from the baseline. It seems to indicate a significant improvement in some patients after the treatment.*
Figure 3 (Pregabalin Fig03)
Figure 4 (Pregabalin Fig04)
This text provides information about the improvement in pain of patients who are parents. The treatments discussed are Pregabalin at two different dosages, and a placebo. The improvement is measured from baseline, and the dosages mentioned include 200 mg three times a day and 100 mg three times a day.*
Figure 5 (Pregabalin Fig05)
The text provides a comparison of the effectiveness of Fregabalin 100 mg three times a day, Pregabalin 80 mg three times a day, and Placebo in improving the condition of patients. It includes a chart showing the percentage of patients improved with each treatment and their corresponding percentage improvement in pain from baseline.*
Figure 6 (Pregabalin Fig06)
This text contains information about various studies comparing the effectiveness of different dosages of a treatment compared to a placebo. The study shows statistically significant results of 150mg/day, 300mg/day, and 600mg/day compared to the placebo group.*
Figure 7 (Pregabalin Fig07)
Figure 9 (Pregabalin Fig08)
This text provides information on the percentage of patients improved with different doses of pregabalin, comparing a 300mg daily dose with a 450mg daily dose, as well as a placebo. The graph also shows the percentage improvement in pain from baseline.*
Figure 10 (Pregabalin Fig09)
This text provides estimated percentages of subjects without LTR (Long-Term Recovery), comparing the outcomes between Progabain and Placebo treatments over a certain number of days around 20 to 180. The data shows the percentage distribution of subjects experiencing different levels of recovery, with values ranging from 0% to 100%.*
Figure 11 (Pregabalin Fig10)
This text provides information on the percentage of subjects improved over time, specifically from baseline to week 12 under different treatments such as Pregetalin and Placeso. The data indicates the percentage of improvement and the treatment being evaluated.*
Figure 12 (Pregabalin Fig11)
This text provides information on the percentage of subjects who showed improvement from baseline to week 16 in a study involving the drug Pregabalin and a placebo. The percentages indicate the level of improvement observed in the subjects over the course of the study.*
Figure 13 (Pregabalin Fig13)
The text provides information on Responder Rate (%) for different doses, including 40.6%, 29.1%, and 22.6%. Additionally, it mentions a placebo at doses of 2.5 mg/kg/day and 10 mg/kg/day with a responder rate of 9%.*
Cockcroft And Gault Equation (Pregabalin Formula)
This text provides a formula for calculating the creatinine clearance (CLCT) which is a measure of kidney function. The formula involves subtracting 140 from the age in years, multiplying it by the weight in kilograms, and then multiplying the result by serum creatinine level in mg/dL. Adjustments are needed based on gender.*
Chemical Structure (Pregabalin Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
